Hans P, Ledoux D, Bonhomme V, Brichant J F
University Department of Anesthesia and Intensive Care Medicine, CHR de la Citadelle, Liege, Belgium.
J Neurosurg Anesthesiol. 1995 Oct;7(4):254-8. doi: 10.1097/00008506-199510000-00003.
Patients receiving anticonvulsants are resistant to nondepolarizing muscle relaxants (NDMR). This study examines the effect of plasma anticonvulsant levels on pipecuronium-induced neuromuscular blockade. Twenty adult patients scheduled for neurosurgery were assigned to one of two groups. Group 0 (G0) consisted of 10 patients not on anticonvulsant therapy; group 1 (G1) included 10 patients treated either with phenytoin or carbamazepine. G1 patients were further divided into G1u (n = 4) and G1w (n = 6) subgroups, according to the plasma anticonvulsant level measured the day before surgery--under (G1u) or within (G1w) the therapeutic range. Neuromuscular transmission was monitored with a Biometer International A/S Accelograph. Anesthesia was induced and maintained using propofol and sufentanil. After calibration of the accelograph, a bolus of pipecuronium 0.08 mg/kg was given IV. The time from pipecuronium injection to the peak reduction of T1 was taken as the onset time. The time in min from pipecuronium injection to recovery of T1% (first accelograph response/baseline response) x 100 and TR% (fourth accelograph response/first accelograph response) x 100 were recorded at 25, 50, and 75% of baseline. The recovery index (RI) was taken as the time from 25 to 75% of baseline. The recovery index (RI) was taken as the time from 25 to 75% recovery of the baseline response. The onset time was not different in G0 (203 +/- 60.4 s), G1 (230.5 +/- 79.3 s), and G1u (181.8 +/- 60.4 s) but prolonged in G1w (279.2 +/- 67.7 s).(ABSTRACT TRUNCATED AT 250 WORDS)
接受抗惊厥药治疗的患者对非去极化肌松药(NDMR)耐药。本研究探讨血浆抗惊厥药水平对哌库溴铵诱导的神经肌肉阻滞的影响。20例计划行神经外科手术的成年患者被分为两组。0组(G0)由10例未接受抗惊厥治疗的患者组成;1组(G1)包括10例接受苯妥英或卡马西平治疗的患者。根据术前一天测得的血浆抗惊厥药水平,G1组患者进一步分为G1u(n = 4)和G1w(n = 6)亚组——低于(G1u)或在(G1w)治疗范围内。使用Biometer International A/S加速仪监测神经肌肉传递。采用丙泊酚和舒芬太尼诱导并维持麻醉。加速仪校准后,静脉注射0.08 mg/kg哌库溴铵。从注射哌库溴铵至T1峰值降低的时间作为起效时间。在基线的25%、50%和75%时,记录从注射哌库溴铵至T1恢复至(首次加速仪反应/基线反应)×100(T1%)和(第四次加速仪反应/首次加速仪反应)×100(TR%)的时间(分钟)。恢复指数(RI)为从基线的25%至75%的时间。恢复指数(RI)为从基线反应恢复至25%至75%的时间。G0组(203±60.4秒)、G1组(230.5±79.3秒)和G1u组(181.8±60.4秒)的起效时间无差异,但G1w组(279.2±67.7秒)延长。(摘要截选至250字)